Inner Cosmos

Inner Cosmos is a neurotechnology company treating depression with its Digital Pill, the first embedded brain-computer interface (BCI) designed for mental health treatment. The minimally invasive in-bone device can be implanted in a one-hour outpatient procedure and provides results similar to or better than TMS therapy. The Digital Pill reads and stimulates brain networks to bring them back into balance without invasive surgery, offering precision, embedded, and mobile therapy that eliminates the need for multiple clinic visits. Inner Cosmos received FDA IDE approval for the first clinical trial for depression in nearly 20 years, and has completed early feasibility studies with three patients at Washington University School of Medicine, with one patient achieving remission after 17 years of severe depression. Founded in 2017, headquartered in Portola Valley, United States, The company has raised $11.9M at the Seed stage, backed by investors including Lool Ventures, KittyHawk Ventures, Loup Funds, Brainstorm Ventures, Masnavi Capital..